​

Funding Round

Series A - Arrakis Therapeutics

Series A - Arrakis Therapeutics

Investment Firm

Overview

Arrakis Therapeutics is a biopharmaceutical developing drugs for neurological disorders and other diseases.

Announced Date

Feb 27, 2017

Funding Type

Series A

Highlights

Location

United States, North America

Social

Investor Lead

Canaan Partners

Canaan Partners

Canaan Partners is a early_stage_venture and late_stage_venture and seed and venture firm.

Participant Investors

6

Investor Name
Participant InvestorCelgene
Participant InvestorPfizer
Participant InvestorAdvent Life Sciences
Participant InvestorCanaan Partners
Participant InvestorOUP (Osage University Partners)

Round Details and Background

Arrakis Therapeutics raised $38000000 on 2017-02-27 in Series A

Arrakis Therapeutics is a biopharmaceutical developing drugs for neurological disorders and other diseases.

Company Funding History

2

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Apr 18, 2019
Series B - Arrakis Therapeutics
13-75.0M
Feb 27, 2017
Series A - Arrakis Therapeutics
6-38.0M

Recent Activity

There is no recent news or activity for this profile.